Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julie Buird

Physician Assistant Augusta, GA Physician Assistant

NPI 1205028115 CMS profile 10495048

3630 J Dewey Gray Cir, Augusta, GA 30909

Open in the dashboard

General payments

$17,010

786 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julie Buird of Augusta, GA is reported in the CMS Open Payments database as having received $17,010 across 786 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,275 169
2024 General $3,228 146
2023 General $3,329 185
2022 General $3,488 165
2021 General $2,690 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Buird
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Julie Buird were reported at $4,275. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Julie Buird Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,690 $132 $37–$438 $132
2022 $3,488 $155 $48–$522 $149
2023 $3,329 $167 $52–$557 $160
2024 $3,228 $178 $55–$600 $164
2025 $4,275 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,356 120 payments
  2. GlaxoSmithKline, LLC. $1,827 92 payments
  3. Mallinckrodt Hospital Products Inc. $1,430 68 payments
  4. Actelion Pharmaceuticals US, Inc. $1,375 36 payments
  5. Harmony Biosciences LLC $1,329 61 payments
  6. Jazz Pharmaceuticals Inc. $1,146 66 payments
  7. ANI Pharmaceuticals, Inc. $738 45 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $726 39 payments
  9. Axsome Therapeutics, Inc. $582 22 payments
  10. Regeneron Healthcare Solutions, Inc. $501 18 payments
  11. Other $3,999 219 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,417 776 payments
  2. Education $593 10 payments
Products named General payments · program years 2021–2025
  1. ACTHAR $1,430 68 payments
  2. OPSUMIT $1,288 31 payments
  3. XYWAV $1,084 62 payments
  4. UPTRAVI $952 20 payments
  5. TEZSPIRE $927 30 payments
  6. BREZTRI $926 37 payments
  7. TRELEGY ELLIPTA $911 68 payments
  8. Wakix $657 22 payments
  9. FASENRA $630 20 payments
  10. Sunosi $582 22 payments
  11. Other $8,770 464 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,222

Median for Physician Assistant: 241

Drug cost

$1,410,130

Median for Physician Assistant: $4,110

Branded share of claims

63.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Acthar Corticotropin Brand 18 $773,575
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 469 $370,480
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 145 $110,886
Breo Ellipta Fluticasone/Vilanterol Brand 69 $27,872
Spiriva Respimat Tiotropium Bromide Brand 35 $23,838
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 28 $17,305
Symbicort Budesonide/Formoterol Fumarate Brand 56 $15,534
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 23 $14,580
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 27 $14,178
Albuterol Sulfate Hfa Albuterol Sulfate Brand 407 $11,998

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
$342 — —
XYWAV
$295 — —
TEZSPIRE
$249 — —
AIRSUPRA
$248 — —
WAKIX
$238 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

786 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record